On May 8, 2020 (the Closing Date), AbbVie Inc. (AbbVie) completed the previously announced acquisition of Allergan plc (Allergan). In connection with the completion of the Acquisition, effective following the effective time of the Scheme, AbbVie expanded the size of its Board of Directors (the Board") from eleven directors to twelve directors and appointed Thomas Freyman to the Board as a Class I director. In addition, Mr. Freyman has been appointed to serve on AbbVie's Compensation Committee. Mr. Freyman formerly served on the board of directors of Allergan.